PharmAthene hits 36 mo. product stability for anthrax vax; Adamis receives cancer vax patent in Europe;

Vaccine Research

PharmAthene's recombinant protective antigen anthrax vaccine has achieved 36 month product stability. That milestone has been an issue for past PharmAthene anthrax vaccines. PharmAthene release

Vical presented data on Transvax, CyMVectin, the RapidResponse platform and its herpes simplex vaccine at the DNA Vaccines 2011 conference in San Diego. Vical release

Vaccine Market

San Diego-based Adamis Pharmaceuticals has received a European patent for its technology that helps form its TeloB-VAX, a cell-based cancer vaccine. The patent is titled "Somatic transgene immunization and related methods." Release

RXi Pharmaceuticals gained multiple patents for its experimental breast cancer vaccine, both for treatment using the vaccine with Herceptin and without. Item

And Finally... Know a college student looking to enter the vaccine industry? Tri-College University in Fargo, ND will establish a vaccinology minor this fall. The minor will be a joint effort between Minnesota State University Moorhead, Concordia College and North Dakota State University, with 8 students from each school studying the curriculum. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.